Vera Therapeutics, Inc. VERA
30.57 USD +0.32 (+1.06%)
Nov 3, 2026, 3:53 PM EST
29.90 Day range 31.19
23.05 52-week range 56.05
- YTD
- -39.63%
- 1 year
- +17.85%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 74.20 +142.7% upside
Now 30.57
- Target (low)
- 34.00
- Target (mean)
- 74.20
- Target (high)
- 100.00
Ratings (0m) 15 13 buy · 2 hold · 0 sell
- Strong buy1
- Buy12
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 14
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.61 | -1.80 – -1.39 | -1.26 | -27.6% | 3.74M | 0.0% | 9 |
| Next quarter | -1.54 | -2.18 – -1.21 | -1.39 | -10.9% | 17.44M | 0.0% | 9 |
| Current year | -6.25 | -7.23 – -5.77 | -4.66 | -34.2% | 24.83M | 0.0% | 10 |
| Next year | -4.25 | -6.72 – -2.23 | -6.25 | +32.0% | 233.76M | +841.4% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Leerink Partners | Initiated | — | Market Perform |
| Sep 8, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 17, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Aug 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 11, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jul 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jul 8, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 8, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jul 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 7, 2026 | B of A Securities | Maintained | Buy | Buy |
| May 15, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Mar 11, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Mar 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 19, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 19, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 19, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 11, 2025 | Wedbush | Maintained | Neutral | Neutral |
| Dec 8, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Dec 5, 2025 | TD Cowen | Maintained | Buy | Buy |
| Nov 10, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 16, 2025 | B of A Securities | Initiated | — | Buy |
| Aug 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 4, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Jun 2, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jun 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 12, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| May 7, 2025 | Wedbush | Maintained | Neutral | Neutral |
| May 7, 2025 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Mar 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |